trial

Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia

NCTId NCT02775864
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 81,921 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2018-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
81,921 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2015-07
Primary completion
2018-04
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
AntipsychoticAntidepressantBenzodiazepineMood stabilizer

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
Rutgers UniversityCollaborator
Patient-Centered Outcomes Research InstituteCollaborator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
81,921
Phase
NA
Primary Completion Date
2018-04
Status
COMPLETED
relationships
The graph out of here
drug
Antipsychotic
drug
Antidepressant
drug
Benzodiazepine
drug
Mood stabilizer
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
Rutgers University
company
Patient-Centered Outcomes Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication